InMed Pharmaceuticals Advancing Innovative Treatment for AMD
InMed Pharmaceuticals Advancing Innovative Treatment for AMD
Key Takeaways (TLDR)
InMed Pharmaceuticals is at the forefront of developing innovative treatment for age-related macular degeneration with its flagship product INM-089 showing great promise.
INM is a clinical stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
The potential treatment for dry AMD by InMed Pharmaceuticals has the ability to improve vision and provide new treatment alternatives for those affected by this prevalent eye condition.
Results from several in vitro and in vivo studies have demonstrated several pharmacological effects in the potential treatment of dry AMD, offering hope for those affected by this condition.
Why it Matters
This news matters as it highlights the groundbreaking work by InMed Pharmaceuticals in developing innovative treatment for age-related macular degeneration, a prevalent eye condition affecting older adults. The company's flagship product INM-089 shows great promise, offering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. This development has the potential to significantly impact the healthcare industry and improve treatment options for individuals affected by AMD.
Summary
InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company, is developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. The company is at the forefront of developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need. InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, serving a spectrum of consumer markets, including pharmaceutical and health and wellness.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InMed Pharmaceuticals Advancing Innovative Treatment for AMD.